Semax

Semax 10MG

Semax 10MG is a synthetic heptapeptide research compound derived from the ACTH(4–10) peptide sequence. It has been investigated primarily in neurobiology, neurotrophic signaling, cognitive research, and experimental neuroprotection.

Research Context

Laboratory studies have investigated Semax in relation to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), Trk receptor signaling, and neuronal cellular responses. Experimental research has reported changes in neurotrophin gene and protein expression following Semax exposure, particularly in rodent brain model.

Research Overview

Research involving Semax may examine neurotrophic signaling, neuronal stress responses, cellular communication, gene expression, and molecular pathways associated with experimental neuroprotection. Much of the mechanistic evidence is preclinical, so findings from laboratory models should not be interpreted as established clinical efficacy.

Key Research Focus Areas

• Neurotrophic Signaling: Investigation of BDNF, NGF, and associated Trk receptor pathways.
• Neurobiology Research: Study of peptide-associated neuronal and glial cellular responses.
• Gene Expression Studies: Evaluation of changes in neurotrophin-related gene expression in experimental models.
• Neuroprotection Research: Investigation of cellular and molecular responses in experimental models of neurological stress and ischemia.
• Peptide Characterization: Evaluation of identity, purity, stability, compatibility, and analytical properties under standardized research protocols.

Important Compliance and Safety Information

Semax is not an FDA-approved human therapeutic in the United States. Research-grade material should be handled only by qualified professionals in controlled laboratory environments, and preclinical findings should not be represented as established human safety or efficacy.

For research use only. Not for human or animal consumption.